Key result
Review compares prediabetes therapies including Subetta, metformin, and GLP-1 receptor agonists.
Answers are grounded in this paper and cite their sources.
This review summarizes current data on the epidemiology, pathogenesis, diagnosis, and pharmacological management of prediabetes, highlighting its bidirectional relationship with cardiovascular disease.
Prediabetes is a clinical condition characterized by impaired glucose tolerance, insulin resistance, and an increased risk of developing type 2 diabetes mellitus. In addition to its progression to diabetes, prediabetes is an independent risk factor for cardiovascular diseases (CVD) due to a complex of pathophysiological mechanisms, including endothelial dysfunction, chronic inflammation, and lipid metabolism disorders. Moreover, the presence of CVD itself can contribute to worsening insulin sensitivity, thereby increasing the likelihood of developing prediabetes. This article presents current data on the epidemiology, pathogenesis, diagnostic methods, and pharmacotherapy of prediabetes, along with a comparative analysis of pharmacological approaches, including Subetta ® , metformin and GLP-1 receptor agonists.
No takes yet. Share an insight, caveat, or question.
Барсуков et al. (2025) conducted a review in Prediabetes. Pharmacotherapy (Subetta, metformin, GLP-1 receptor agonists) was evaluated. This review summarizes current data on the epidemiology, pathogenesis, and diagnostic methods of prediabetes, and compares pharmacological approaches including Subetta, metformin, and GLP-1 agonists.
Synapse has enriched 10 related papers. Consider them for comparative context: